Friday, October 16, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Earnings callNasdaq· November 27, 2025

Datadog (DDOG) Q3 2025 Earnings Call Transcript

View original at nasdaq.com
Datadog (DDOG) Q3 2025 Earnings Call Transcript Image source: The Motley Fool. Date Nov. 6, 2025 4:46 p.m. ET Call participants Chief Executive Officer and Co-Founder — Olivier PomelChief Financial Officer — David ObstlerVice President, Investor Relations — Yuka Broderick Need a quote from a Motley Fool analyst?…
Opening lines of the source · Nasdaq · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Cloud plus AI TAM expected to grow to trillions of dollars

    80% confidence
  • Non-AI customer YoY growth accelerated to 20% in Q3 from 18% in Q2

    80% confidence
  • October trends show non-AI growth acceleration continuing

    80% confidence
  • New logo annualized bookings more than doubled year-over-year, reaching a new record

    80% confidence
  • LLM spans sent quadrupled in recent months

    80% confidence
  • The portion of year-over-year revenue growth related to new customers was about 25% in Q3, up from 20% in Q2

    80% confidence
  • Bits AI Security Agent automates 90% of issue triage

    80% confidence
  • GPU monitoring products don't generate any significant revenue yet and represent a future opportunity

    80% confidence
  • The sequential usage growth for non-AI existing customers was the highest seen going back 12 quarters

    80% confidence
  • Customer reported that with Bits AI SRE being on call 24/7, mean time to resolution for services has improved significantly

    80% confidence
  • Customer reported being very hooked on Datadog due to the MCP server tool

    80% confidence
  • Long-term gross margin target remains plus or minus 80%, unchanged

    80% confidence
  • Operating expense growth was 32% YoY in Q3, down from 36% in Q2

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com